Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Checkpoint Names James Oliviero President & CEO | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Checkpoint Names James Oliviero President & CEO

Michael Weiss to continue as executive chairman

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Checkpoint Therapeutics Inc., a Fortress Biotech Company, has named James Oliviero as president and chief executive officer. Mr. Oliviero will also be appointed to Checkpoint’s board. Michael Weiss, will remain as executive chairman.

“We are very excited to have James join Checkpoint. James is a seasoned biotech executive with strong operational and financial expertise. James’ experience ranges from capital raising and managing relationships with Wall Street to playing an instrumental role in the approval of Auryxia, a drug we licensed and developed together at Keryx. Those skills will prove invaluable as we drive to build and grow Checkpoint into a major immuno-oncology company,” said Mr. Weiss.

Mr. Oliviero has over fifteen years of operational experience in the biotechnology industry. From May 2003 to September 2015, he served in a variety of leadership capacities at Keryx Biopharmaceuticals, most recently as its chief financial officer since April 2009, where he was instrumental in the growth of the company to a market capitalization over $1 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters